Search

Your search keyword '"Hinz U"' showing total 91 results

Search Constraints

Start Over You searched for: Author "Hinz U" Remove constraint Author: "Hinz U" Topic pancreatic neoplasms Remove constraint Topic: pancreatic neoplasms
91 results on '"Hinz U"'

Search Results

1. Portal vein resection in pancreatic neuroendocrine neoplasms.

2. Distal Pancreatectomy: Extent of Resection Determines Surgical Risk Categories.

3. Distal Pancreatectomy With En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer: A Safe and Effective Procedure.

4. Farnesoid X receptor activation inhibits pancreatic carcinogenesis.

5. Surgery for intraductal papillary mucinous neoplasms in young patients: High-risk population.

6. Central pancreatectomy prevents postoperative diabetes.

7. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival.

8. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer.

9. Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).

10. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.

11. Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival.

12. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcinoma.

13. Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy.

14. Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms.

15. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma.

16. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer.

17. Enucleation for low-grade branch duct intraductal papillary mucinous neoplasms: Long-term follow-up.

18. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.

19. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?

20. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve.

21. The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes.

22. Epidemiological Factors Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Dual Center Case-Control Study.

23. Categorization of Differing Types of Total Pancreatectomy.

24. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score.

25. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.

26. C-reactive protein independently predicts survival in pancreatic neuroendocrine neoplasms.

27. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery.

28. Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm.

29. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.

30. Enucleation for benign or borderline tumors of the pancreas: comparing open and minimally invasive surgery.

31. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.

32. Presentation and outcome of mixed neuroendocrine non-neuroendocrine neoplasms of the pancreas.

34. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.

35. Outcome and prognosis after pancreatectomy in patients with solid pseudopapillary neoplasms.

36. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.

37. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.

38. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.

39. Sphincter of Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy.

40. Enucleation: A treatment alternative for branch duct intraductal papillary mucinous neoplasms.

41. Pancreatic Cancer Surgery: The New R-status Counts.

42. Radical surgery of oligometastatic pancreatic cancer.

43. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.

44. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.

45. Main-duct Intraductal Papillary Mucinous Neoplasm: High Cancer Risk in Duct Diameter of 5 to 9 mm.

46. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.

47. Risk of pancreatic fistula after enucleation of pancreatic tumours.

48. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.

49. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories.

50. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.

Catalog

Books, media, physical & digital resources